CD34 Marker Enrichment for Biological Pacemaker Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bradyarrhythmia, such as electronic pacemaker implantation, come with high complication rates, lack of autonomic responsiveness, and inability to adapt to body growth, particularly in pediatric patients, highlighting the need for biological pacemakers that can integrate with the cardiac conduction system and grow with the heart.
Innovation Solution
A method to detect and enrich sinoatrial node-like pacemaker cardiomyocytes (SANLPCs) using specific markers like CD34, allowing for the generation of a cardiomyocyte population that can be used to create a biological pacemaker capable of integrating with the native cardiac conduction system and adapting to the heart's growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If electronic pacemaker implantation is used to treat bradyarrhythmia, then heart rate regulation is achieved, but complication rate increases and autonomic responsiveness is lost
Solution Approach 1:
The patent replaces the mechanical/electronic pacemaker system with a biological cell-based system. Human pluripotent stem cell-derived cardiomyocytes are transplanted into the right atrial appendage to provide pacemaker function, substituting the electronic device with a living tissue solution that can integrate with the host's cardiac system and respond to autonomic signals naturally.
Solution Approach 2:
The patent uses an intermediary substance (ichthyocol gel) to deliver and retain the transplanted cardiomyocytes at the implantation site. The gel acts as a carrier that maintains cell viability and facilitates integration with the native cardiac tissue, thereby reducing complications while achieving reliable heart rate regulation.
2Reliability
If electronic pacemaker implantation is used, then heart rate control is achieved, but adaptability to body growth is lost
Solution Approach 1:
The patent employs a dynamic, living tissue solution instead of a static electronic device. The transplanted cardiomyocytes are living cells that can grow, divide, and adapt to the host's body growth, particularly in pediatric patients. This biological system dynamically adjusts to changing physiological conditions and body size, providing long-term adaptability that electronic pacemakers cannot achieve.
3Adaptability or versatility
If mixed populations of cardiomyocytes are transplanted, then biological pacemaker function is achieved, but success rate decreases due to heterogeneity
Solution Approach 1:
The patent extracts and isolates specific pacemaker-capable cardiomyocyte subpopulations from the mixed cardiomyocyte culture. By using flow cytometry and specific surface markers (such as CD41, CD42, or CD61), the invention separates the effective pacemaker cells from non-functional or less functional cells, thereby increasing the success rate of biological pacemaker transplantation while maintaining the biological functionality.
Solution Approach 2:
The patent applies local quality by creating a heterogeneous cell population with specific spatial distribution. The transplanted cell mixture contains different types of cardiomyocytes with varying pacemaker potentials, and through natural selection and local adaptation at the implantation site, the most suitable cells establish pacemaker function. This approach allows the system to have different functional zones within the transplant that collectively achieve reliable pacemaker activity.
Data Source
AI summary
The invention relates to the use of CD34 as a cell surface marker to detect sinoatrial node-like pacemaker cells (SANLPCs) in a population of cells and to generate cell preparations highly enriched for SANLPCs. Also provides herein are methods of using SANLPC-enriched cell preparations for cardiac cell therapy.